UMC Clinical Trials

    • Principal Investigator

      Agustin Garcia, MD

    • Category

      Oncology - Female Reproductive

    • Title of Protocol

      A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma.

    • Brief Description

      Additional Information

    • Research Phone
      # 504.407.7395

    • Principal Investigator

      Agustin Garcia, MD

    • Category

      Oncology - Breast

    • Title of Protocol

      A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer.

    • Brief Description

      Additional Information

    • Research Phone
      # 504.407.7395

    • Principal Investigator

      Agustin Garcia, MD

    • Category

      Oncology - Cervical

    • Title of Protocol

      A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma.

    • Brief Description

      Additional Information

    • Research Phone
      # 504.407.7395

    • Principal Investigator

      Agustin Garcia, MD

    • Category

      Oncology - Melanoma/Breast

    • Title of Protocol

      A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment with Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Research Phone
      # 504.407.7395

    • Principal Investigator

      Augusto Ochoa, MD

    • Category

      Oncology - Breast

    • Title of Protocol

      A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Research Phone
      # 504.407.7395

    • Principal Investigator

      Augusto Ochoa, MD

    • Category

      Oncology - Multiple

    • Title of Protocol

      S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors Treatment with Ipilimumab and Nivolumab for Rare Cancers

    • Brief Description

      Additional Information

    • Recruitment Contact

      Research Phone
      # 504.407.7395

    • Principal Investigator

      Augusto Ochoa, MD

    • Category

      Oncology - Breast/ Gynecologic

    • Title of Protocol

      NRG-CC004 Phase Ii Double Blind Dose Finding Trial of Bupropion Versus Placebo For Sexual Desire In Women With Breast Or Gynecologic Cancer.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Research Phone
      # 504.407.7395

    • Principal Investigator

      Augusto Ochoa, MD

    • Category

      Oncology - Melanoma

    • Title of Protocol

      A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Research Phone
      # 504.407.7395

    • Principal Investigator

      Augusto Ochoa, MD

    • Category

      Oncology - Renal

    • Title of Protocol

      S1500; A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET).

    • Brief Description

      Additional Information

    • Recruitment Contact

      Research Phone
      # 504.407.7395

    • Principal Investigator

      Augusto Ochoa, MD

    • Category

      Oncology - Pancreatic

    • Title of Protocol

      S1505; A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Research Phone
      # 504.407.7395

    • Principal Investigator

      Augusto Ochoa, MD

    • Category

      Oncology - Melanoma

    • Title of Protocol

      EA6141 Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Research Phone
      # 504.407.7395

    • Principal Investigator

      Augusto Ochoa, MD

    • Category

      Oncology - Breast

    • Title of Protocol

      Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Research Phone
      # 504.407.7395

    • Principal Investigator

      Cindy Leissinger, MD

    • Category

      Hematology - Hemophilia

    • Title of Protocol

      An Open-Label, Multicenter, Expanded Access Program For Emicizumab in Patents With Hemophilia and With Inhibitors.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Melody Benton:
      mbenton@tulane.edu
      or 504.988.3596

    • Principal Investigator

      David Janz, MD

    • Category

      Pulmonology

    • Title of Protocol

      VIOLET: Vitamin D to Improve Outcomes by Leveraging Early Treatment.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Paula Lauto:
      plauto@lsuhsc.edu
      or 504.568.4634

    • Principal Investigator

      Frank Smart, MD

    • Category

      Cardiology

    • Title of Protocol

      Medtronic Reveal LINQ Heart Failure Study

    • Brief Description

      Additional Information

    • Recruitment Contact

      Jacob Simon:
      jsimo9@lsuhsc.edu
      or 504.568.2349

    • Principal Investigator

      Frank Smart, MD

    • Category

      Cardiology

    • Title of Protocol

      A Double-blind, Randomized, Placebo-controlled, Multicenter Study to
      Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Jacob Simon:
      jsimo9@lsuhsc.edu
      or 504.568.2349

    • Principal Investigator

      Frank Smart, MD

    • Category

      Cardiology

    • Title of Protocol

      A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF)- EMPEROR-Preserved.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Jacob Simon:
      jsimo9@lsuhsc.edu
      or 504.568.2349

    • Principal Investigator

      Juzar Ali, MD

    • Category

      Pulmonology

    • Title of Protocol

      An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium complex (MAC) That are Refractory to Treatment.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Maureen Vincent:
      mvince@lsuhsc.edu
      or 504.568.4581

    • Principal Investigator

      Jyotsna Fuloria, MD

    • Category

      Oncology - Pancreatic

    • Title of Protocol

      A Phase II Multi-Center Study of SM-88 in Subjects with Pancreatic Cancer Whose Disease Has Progressed or Recurred after/on First Line Chemotherapy

    • Brief Description

      Additional Information

    • Recruitment Contact

      Shana Lennard:
      shana.lennard@lcmchealth.org
      or 504.702.5171

    • Principal Investigator

      Jyotsna Fuloria, MD

    • Category

      Hematology - Sickle Cell

    • Title of Protocol

      A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Shana Lennard:
      shana.lennard@lcmchealth.org
      or 504.702.5171

    • Principal Investigator

      Jyotsna Fuloria, MD

    • Category

      Oncology - Relapsed of Refractory Multiple Myeloma and Relapsed or Refractory Acute Myeloid Leukemia

    • Title of Protocol

    • A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

    • Brief Description

      Additional Information

    • Recruitment Contact

      Shana Lennard:
      shana.lennard@lcmchealth.org
      or 504.702

    • Principal Investigator

      Jyotsna Fuloria, MD

    • Category

      Oncology - Non-Small Cell Lung Cancer

    • Title of Protocol

      Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Shana Lennard:
      shana.lennard@lcmchealth.org
      or 504.702

    • Principal Investigator

      Kara De Felice, MD

    • Category

      Gastroenterology

    • Title of Protocol

      An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy with the Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects with Crohn's Disease Stratified at Higher Risk for Developing Complications.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Marie Sandi, FNP-BC:
      mchild@lsuhsc.edu
      or 504.568.3450

    • Principal Investigator

      Matthew Lammi, MD

    • Category

      Pulmonology

    • Title of Protocol

      TRITON: The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-controlled, Phase 3b study

    • Brief Description

      Additional Information

    • Recruitment Contact

      Paula Lauto:
      plauto@lsuhsc.edu
      or 504.568.4634

    • Principal Investigator

      Michael Hagensee, MD

    • Category

      Infectious Disease

    • Title of Protocol

      ANCHOR: Anal Cancer/HSIL Outcomes Research Study

    • Brief Description

      Additional Information

    • Recruitment Contact

      Cara Rowe, MSW: cjoh26@lsuhsc.edu
      or 504.568.4640

    • Principal Investigator

      Michael Hagensee, MD

    • Category

      Infectious Disease

    • Title of Protocol

      SYN-078-301: Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients with Fungal Diseases that are Refractory to or Intolerant of Standard Antifungal Treatment

    • Brief Description

      Additional Information

    • Recruitment Contact

      Cara Rowe, MSW:
      cjoh26@lsuhsc.edu
      or 504.568.4640

    • Principal Investigator

      Michelle Loch, MD

    • Category

      Oncology - Breast

    • Title of Protocol

      A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination with Atezolizumab or Placebo in Patients with HER-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane based Therapy (Main)

    • Brief Description

      Additional Information

    • Recruitment Contact

      Research Phone
      # 504.407.7395

    • Principal Investigator

      Nathan Nielsen, MD

    • Category

      Pulmonolgy/Critical Care

    • Title of Protocol

      LJ501-EAP01 EXPANDED ACCESS FOR LJPC-501

    • Brief Description

      Additional Information

    • Recruitment Contact

      Nathan Nielsen, MD:
      nnielsen@tulane.edu
      or 504.988.3833

    • Principal Investigator

      Oren Tessler, MD

    • Category

      Plastic Surgery

    • Title of Protocol

      MTF 16-04-01: A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing, Prosthetic Acellular Dermal Matrix (ADM) Assisted Immediate Post-Mastectomy Breast Reconstruction.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Allison Fleury, RN:
      afleur@lsuhsc.edu
      or 504.903.9000

    • Principal Investigator

      Patrick Greiffenstein, MD

    • Category

      Surgery

    • Title of Protocol

      ACCUTE ATB-202 A Phase III Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of AB103 as Compared to Placebo in Patients with Necrotizing Soft Tissue Infections (NSTI)

    • Brief Description

      Additional Information

    • Recruitment Contact

      Allison Fleury, RN: afleur@lsuhsc.edu
      or 504.903.9000

    • Principal Investigator

      Patrick Greiffenstein, MD

    • Category

      Surgery

    • Title of Protocol

      An Open-Label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Subjects with Thrombocytopenia Scheduled for a Surgical Procedure

    • Brief Description

      Additional Information

    • Recruitment Contact

      Allison Fleury, RN:
      afleur@lsuhsc.edu
      or 504.903.9000

    • Principal Investigator

      Reinhold Munker, MD

    • Category

      Oncology - Myeloma

    • Title of Protocol

      Randomized Phase III Trial of Lenalidomide versus Observation Alone
      in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

    • Brief Description

      Additional Information

    • Recruitment Contact

      Rachel Cruthirds:
      rcruthir@tulane.edu

    • Principal Investigator

      Reinhold Munker, MD

    • Category

      Oncology - Multiple

    • Title of Protocol

      [766413-1] EAY131: Molecular Analysis for Therapy Choice (MATCH)

    • Brief Description

      Additional Information

    • Recruitment Contact

      Rachel Cruthirds:
      rcruthir@tulane.edu

    • Principal Investigator

      Tammuella Singleton, MD

    • Category

      Hematology - Hemophilia

    • Title of Protocol

      An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B

    • Brief Description

      Additional Information

    • Recruitment Contact

      Melody Benton:
      mbenton@tulane.edu
      or 504.988.3596

    • Principal Investigator

      Tammuella Singleton, MD

    • Category

      Hematology - Hemophilia

    • Title of Protocol

      An open-label single-arm multicentre non-controlled phase 3a trial investigating safety and efficacy of N8-GP in prophylaxis and treatment of bleeding episodes in previously untreated paediatric patients with severe haemophilia A.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Melody Benton:
      mbenton@tulane.edu
      or 504.988.3596

    • Principal Investigator

      Thomas Reske, MD

    • Category

      Oncology - Liver

    • Title of Protocol

      A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as 2nd-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma.

    • Brief Description

      Additional Information

    • Recruitment Contact

      Research Phone
      # 504.407.7395

There are no Events to display.